The global therapeutic apheresis market, valued at $3.84 billion in 2025, is projected to grow to $8.94 billion by 2035 at a 7.9% CAGR. Growth is fueled by rising chronic and autoimmune diseases, advances in automated apheresis technology, and expanding healthcare infrastructure, especially in North America and Asia Pacific. Key players include Terumo BCT, Fresenius Kabi, and Haemonetics. The market covers devices, consumables, and procedures for treating neurological, hematological, renal, cardiovascular, and autoimmune disorders. Increasing awareness, reimbursement improvements, and government initiatives also support expansion.
The Nasdaq 100 completed its June quarterly rebalance, replacing five legacy tech companies with five innovation-focused firms including CoreWeave and Rocket Lab. This shift reflects a move toward next-gen hardware, AI infrastructure, and space tech....
The Global X Robotics & Artificial Intelligence ETF (BOTZ) is a leading U.S.-listed fund providing access to global robotics and AI companies, including major foreign automation firms and U.S. AI chipmakers. It offers investors diversified exposure t...
